Workflow
Chimin(603222)
icon
Search documents
济民健康振幅18.35%,上榜营业部合计净买入6607.95万元
(原标题:济民健康振幅18.35%,上榜营业部合计净买入6607.95万元) 济民健康(603222)今日涨停,全天换手率16.96%,成交额12.02亿元,振幅18.35%。龙虎榜数据显示, 营业部席位合计净买入6607.95万元。 资金流向方面,今日该股主力资金净流入2.37亿元,其中,特大单净流入2.63亿元,大单资金净流出 2593.14万元。近5日主力资金净流入2.90亿元。 融资融券数据显示,该股最新(9月10日)两融余额为1.97亿元,其中,融资余额为1.97亿元,融券余额 为11.50万元。近5日融资余额合计增加22.49万元,增幅为0.11%。融券余额合计增加2.29万元,增幅 24.84%。 8月21日公司发布的半年报数据显示,上半年公司共实现营业收入3.66亿元,同比下降21.30%,实现净 利润-5269.59万元。(数据宝) 证券时报•数据宝统计显示,上榜的前五大买卖营业部合计成交2.89亿元,其中,买入成交额为1.78亿 元,卖出成交额为1.11亿元,合计净买入6607.95万元。 具体来看,今日上榜营业部中,第一大买入营业部为华福证券有限责任公司南京胜太路证券营业部,买 入金额为 ...
医药生物行业今日净流出资金39.75亿元,药明康德等7股净流出资金超亿元
Market Overview - The Shanghai Composite Index rose by 1.65% on September 11, with 31 out of 41 sectors experiencing gains, led by the communication and electronics sectors, which increased by 7.39% and 5.96% respectively [2] - The pharmaceutical and biotechnology sector saw a modest increase of 0.25% [2] Capital Flow Analysis - The net inflow of capital in the two markets reached 34.518 billion yuan, with 11 sectors experiencing net inflows [2] - The electronics sector had the highest net inflow of 21.723 billion yuan, corresponding to its 5.96% increase, followed by the computer sector with a net inflow of 8.479 billion yuan and a daily increase of 3.71% [2] Pharmaceutical and Biotechnology Sector Performance - Within the pharmaceutical and biotechnology sector, there were 474 stocks, with 350 stocks rising and 111 stocks declining [3] - The top three stocks with the highest net inflow were Jimin Health (2.37 billion yuan), Shutai Shen (1.55 billion yuan), and Rejing Bio (1.41 billion yuan) [3] - The sector experienced a net outflow of 3.975 billion yuan, with the largest outflows from WuXi AppTec (3.17 billion yuan), BeiGene (2.29 billion yuan), and Zhaoyan New Drug (1.78 billion yuan) [3][5] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +10.02% with a turnover rate of 16.96% and a capital flow of 236.996 million yuan - Shutai Shen: +7.24% with a turnover rate of 10.87% and a capital flow of 155.111 million yuan - Rejing Bio: +11.40% with a turnover rate of 6.65% and a capital flow of 140.912 million yuan [4] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - WuXi AppTec: -2.41% with a turnover rate of 4.06% and a capital outflow of -317.3795 million yuan - BeiGene: -3.73% with a turnover rate of 11.42% and a capital outflow of -229.1395 million yuan - Zhaoyan New Drug: -2.88% with a turnover rate of 9.44% and a capital outflow of -178.0592 million yuan [5]
医疗器械 ETF(562600)收涨1.25%,持仓股济民健康、振德医疗强势涨停
Mei Ri Jing Ji Xin Wen· 2025-09-11 08:40
Group 1 - The medical device ETF (562600) opened lower but closed up by 1.25%, with leading stocks such as Hotspring Bio rising by 11.40% and Jimin Health and Zhend Medical hitting a strong limit up of 10% [1] - The National Medical Products Administration (NMPA) has focused on key areas such as medical robots, high-end medical imaging, AI medical devices, and new biological materials, approving 52 innovative products this year, totaling 367 approved innovative products to date [1] - Recent high-level discussions emphasized principles like "anti-involution" and "optimizing centralized procurement without solely focusing on low prices," indicating a clear signal for policy shifts supporting the innovative medical device industry [1] Group 2 - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device sector, tracking the CSI All Share Medical Device Index, which includes 100 representative listed companies in core medical fields [2] - The medical device sector accounts for a significant 89.34% of the index, indicating a concentrated focus on capturing the development dividends in this field [2] - As of the first quarter of 2025, the top ten holdings in the medical device ETF (562600) include Mindray Medical and United Imaging, which together account for 22.3% of the ETF [2]
创新药概念有所回暖,济民健康12天6板
Group 1 - The innovative drug concept stocks have shown signs of recovery, with Ji Min Health achieving a six-day consecutive increase [1] - Shu Tai Shen has risen over 7%, while Rejing Bio has increased by more than 5% [1] - Other stocks such as MediX, Guangsheng Tang, and Borui Pharmaceutical have also experienced upward movement [1]
济民健康管理股份有限公司关于股票交易异常波动的公告
Core Viewpoint - The stock of Jimin Health Management Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative closing price deviation exceeding 20% over three consecutive trading days, indicating potential market risks [2][5][9]. Group 1: Stock Trading Abnormalities - The company's stock price increased by a cumulative deviation of 75.32% over the past 30 trading days, suggesting significant volatility that diverges from the company's operational performance [2][9]. - The stock experienced a cumulative closing price deviation of over 20% on September 8, 9, and 10, 2025, qualifying as an abnormal trading situation under the Shanghai Stock Exchange rules [5][9]. Group 2: Company Verification and Response - The company conducted a self-examination and confirmed that there have been no significant changes in its main business or external operating environment, and no undisclosed major events exist [6][7]. - The controlling shareholder disclosed a share reduction plan on September 5, 2025, but no other major transactions or restructuring activities were reported [3][6]. Group 3: Financial Performance - For the first half of 2025, the company reported a net loss of 52.70 million yuan, a decline compared to the same period last year [9].
济民健康(603222) - 关于济民健康管理股份有限公司股票交易异常波动的征询函的回函
2025-09-10 11:01
关于济民健康管理股份有限公司 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025年 9 月 10 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 100%的股权和法人股东台州市梓铭贸易有限公司 100%的股权,为公司实际控 制人。 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) 双鸽集团有限公司 2×年9月/0日 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 本家族全体成员于 2025年9月10 ...
济民健康(603222) - 济民健康管理股份有限公司关于股票交易异常波动的公告
2025-09-10 10:49
●经公司自查并书面征询控股股东及实际控制人,截至本公告披露日,公司 不存在应披露而未披露的重大事项。 ●公司控股股东于 2025 年 9 月 5 日披露了减持股份计划。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险,敬请广大投 资者理性决策,审慎投资。 证券代码:603222 证券简称:济民健康 公告编号:2025-045 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: ●公司股票交易于 2025 年 9 月 8 日、9 月 9 日、9 月 10 日连续三个交易日内 收盘价格涨幅偏离值累计超过 20%,属于《上海证券交易所交易规则》规定的股票 交易异常波动情形。公司股价近 30 个交易日涨幅偏离值累计达 75.32%,剔除大盘 和板块整体因素后的实际涨跌幅波动较大,存在异常交易情形,公司股价走势与 经营业绩趋势相偏离,敬请广大投资者注意二级市场交易风险,理性决策,审慎 投资。 (一)经公司自查,公司主营业务未发生重大变化,内外部经营环境未发生 ...
济民健康录得10天6板
Group 1 - The stock of Jimin Health has experienced a significant increase, with 6 limit-up days in the last 10 trading days, resulting in a cumulative increase of 39.32% and a turnover rate of 177.70% [2] - As of 9:52 AM, the stock's trading volume reached 65.8 million shares, with a transaction amount of 813 million yuan, and a turnover rate of 12.53% [2] - The total market capitalization of Jimin Health in the A-share market is currently 6.679 billion yuan [2] Group 2 - The latest margin trading data shows that as of September 8, the margin balance for the stock is 167 million yuan, with a decrease of 31.4 million yuan from the previous trading day, representing a decline of 15.83% [2] - Over the past 10 days, the margin balance has decreased by a total of 108 million yuan, reflecting a decline of 39.16% [2] - The stock has appeared on the Dragon and Tiger list three times due to significant price deviations, with a net buying amount of 16.35 million yuan from the leading brokerage firms [2] Group 3 - The company's semi-annual report released on August 21 indicates that total operating revenue for the first half of the year was 366 million yuan, a year-on-year decrease of 21.30% [2] - The net profit for the same period was -53 million yuan, representing a year-on-year decline of 307.10% [2]
板块大爆发!成分股联影医疗涨超12%,全市场规模最大的医疗器械ETF(159883)涨超4%
Xin Lang Cai Jing· 2025-09-08 02:25
Group 1 - The medical device sector is experiencing significant growth, with the CSI All Index Medical Device Index (H30217) rising by 3.31% as of September 8, 2025, and key stocks such as United Imaging Healthcare (688271) increasing by 11.64% [1] - The Medical Device ETF (159883) has seen a notable increase of 8.06 billion CNY in scale over the past month, ranking it among the top 25% of comparable funds [2] - The launch of the "5G Brain-Heart Mobile" platform represents a major breakthrough in the field of brain health, marking the first clinical application of a brain-machine interface for Alzheimer's disease [3] Group 2 - The Chinese medical device industry is poised for international expansion, particularly in the European market, which is valued at 160 billion euros in 2023, with steady growth expected [4] - The medical device sector is anticipated to grow in 2025, driven by increased bidding activity for imaging equipment and supportive policies for home medical devices, alongside accelerated international expansion [4] - The medical device ETF (159883) is the largest in the A-share market, covering various segments including medical equipment and consumables, and is positioned for efficient trading [5]
医疗器械概念震荡走高 奥精医疗、开立医疗涨超10%
Mei Ri Jing Ji Xin Wen· 2025-09-08 02:13
Group 1 - The medical device sector experienced a significant upward movement on September 8, with companies such as Aojing Medical, United Imaging Medical, and Kaili Medical seeing stock increases of over 10% [1] - Other companies in the sector, including Jimin Health, BGI Genomics, Dabo Medical, and Mindray Medical, also showed positive stock performance [1]